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Abstract
Background: Point-of-care (POC) hemoglobin testing has the potential to revolutionize massive transfusion
strategies. No prior studies have compared POC and central laboratory testing of hemoglobin in patients
undergoing massive transfusions.
Methods: We retrospectively compared the results of our point-of-care hemoglobin test (EPOC®) to our core laboratory
complete blood count (CBC) hemoglobin test (Sysmex XE-5000™) in patients undergoing massive transfusion protocols
(MTP) for hemorrhage. One hundred seventy paired samples from 90 patients for whom MTP was activated were
collected at a single, tertiary care hospital between 10/2011 and 10/2017. Patients had both an EPOC® and CBC
hemoglobin performed within 30 min of each other during the MTP. We assessed the accuracy of EPOC® hemoglobin
testing using two variables: interchangeability and clinically significant differences from the CBC. The Clinical Laboratory
Improvement Amendments (CLIA) proficiency testing criteria defined interchangeability for measurements. Clinically
significant differences between the tests were defined by an expert panel. We examined whether these relationships
changed as a function of the hemoglobin measured by the EPOC® and specific patient characteristics.
Results: Fifty one percent (86 of 170) of paired samples’ hemoglobin results had an absolute difference of ≤7 and 73%
(124 of 170) fell within ±1 g/dL of each other. The mean difference between EPOC® and CBC hemoglobin had a bias of
− 0.268 g/dL (p = 0.002). When the EPOC® hemoglobin was < 7 g/dL, 30% of the hemoglobin values were within ±7, and
57% were within ±1 g/dL. When the measured EPOC® hemoglobin was ≥7 g/dL, 55% of the EPOC® and CBC hemoglobin
values were within ±7, and 76% were within ±1 g/dL. EPOC® and CBC hemoglobin values that were within ±1 g/dL
varied by patient population: 77% for cardiac surgery, 58% for general surgery, and 72% for non-surgical patients.
Conclusions: The EPOC® device had minor negative bias, was not interchangeable with the CBC hemoglobin, and was
less reliable when the EPOC® value was < 7 g/dL. Clinicians must consider speed versus accuracy, and should check a CBC
within 30 min as confirmation when the EPOC® hemoglobin is < 7 g/dL until further prospective trials are performed in
this population.
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Background
Time is of the essence when it comes to preventing mor-
bidity and mortality for critically ill patients suffering from
massive hemorrhage [1]. POC lab testing has revolutionized
patient care by providing actionable information at the bed-
side in a fraction of the amount of time required for a core
laboratory test result to come back. However, the possible
tradeoff of POC testing is expediency at the expense of
accuracy. Our aim was to examine the utility of POC
hemoglobin testing in patients with acute hemorrhage who
were undergoing massive transfusion of blood products.
Aside from the obvious morbidity and mortality associated
with under resuscitation, there are problems with over
transfusion including: volume overload, respiratory failure,
renal failure, and re-bleeding specifically in the setting of
variceal bleeds [2, 3]. Additionally, over transfusion results
in substantial waste of limited and expensive resources.
Even relatively small discrepancies between POC and core
laboratory hemoglobin values can lead clinicians to choose
very different treatment plans when resuscitating acutely
bleeding patients so it is imperative that these tests be
highly correlated if clinical decision are to be made based
off of them. The purpose of this study was to compare the
hemoglobin results from our institution’s POC lab system
and our core laboratory system in patients undergoing
massive blood-product transfusion for acute blood loss in
order to determine how accurate POC hemoglobin testing
has during the resuscitation of acutely hemorrhaging pa-
tients. We compared the EPOC® Blood Analysis System
(Epocal Inc., Ottawa, Ontario, Canada) to the Sysmex-XE
5000™ core laboratory system (Kobe, Japan). Our goal was
to clarify the usefulness of this test, which could potentially
facilitate early decision-making based on a reliable test in




This was a retrospective chart review at a single-center,
tertiary care hospital in Philadelphia, PA. The study
protocol was reviewed and approved by our institution’s
institutional review board. All patients undergoing
massive transfusion protocol (MTP) between 10/2011
and 10/2017 were identified through the hospital’s elec-
tronic medical record system. The hospital definition for
MTP was “the administration of at least one blood vol-
ume worth of blood, or During an MTP, our blood bank
sends 6 units of packed red blood cells (PRBCs), 4 units
of fresh frozen plasma (FFP), and 1 unit of platelets
(PLTs) per round. These patient’s records were then
reviewed to identify patients that had an EPOC® and
core laboratory hemoglobin specimen drawn within 1 h
of each other on the day of the MTP event. EPOC® and
CBC hemoglobin values, as well as the date and time of
the blood draws were recorded. Additional data col-
lected included patient’s age, sex, diagnosis, hospital ser-
vice, location, and disposition at time of discharge.
Our initial sample population included 98 patients that
had MTP activation, and an EPOC® and CBC
hemoglobin drawn within 60 min of each other. From
these 98 patients, a total of 218 lab comparison points
were obtained. We determined a time cutoff when the
mean differences between EPOC® and CBC samples are
most likely due to actual differences between
hemoglobin values rather than random fluctuations
around a true value. Time intervals were coded into six
categories: 0 (0–1 min); 1 (1–5 min); 2 (5–15 min); 3
(15–30min); 4 (30–45 min); 5 (45–60 min). ANOVA
was performed to assess mean differences between
EPOC® and CBC samples over time. Results indicated
mean differences were statistically significant at specific
time points, F (5, 215) = 3.98, p < 0.01. A Tukey HSD
post hoc analysis further specified that time intervals
when mean hemoglobin differences were statistically dif-
ferent from samples drawn during time interval 0 (tests
that were drawn at the same time) occurred between 30
and 60min, p < 0.05 respectively. Therefore, further ana-
lysis was restricted to only those samples drawn within
30min of each other. The final sample consisted of a
total of 90 individual patients, including 49 cardiac sur-
gery patients, 20 general/trauma surgery patients, and 19
non-surgical patients. Among these patients, 170 lab
comparison points were obtained. Table 1 demonstrates
the average number of blood products transfused, strati-
fied by each patient population.
Hemoglobin measurements
The medical center core laboratory analyzed samples
using a Sysmex-XE 5000™ automated hematology analyzer
in which the hemoglobin was directly determined by ab-
sorbance spectrophotometry and the hematocrit was cal-
culated as a function of mean corpuscular volume and red
blood cell count [4]. The EPOC® Blood Analysis System
directly measured hematocrit using AC conductometry
and the hemoglobin was calculated as a function of the
measured hematocrit, assuming a normal mean corpuscu-
lar hemoglobin concentration (MCV) [5].
Statistical methods
We defined a “clinically significant difference” between
the two tests to be ±1 g/dl based on the a priori opinion
of a panel of three critical care physicians that routinely
treat patients with hemorrhagic shock (MB, BA, FW).
The Clinical Laboratories Improvement Amendments
(CLIA) criteria for interchangeability of lab tests states
that hemoglobin measurements must be within ±7% of
one another to be considered interchangeable tests [6].
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The Bland-Altman method was performed to examine
agreement between measured EPOC® and CBC
hemoglobin values. This method of analysis is useful when
comparing new measurements with the “gold standard”
and assists with evaluating the degree of agreement or dis-
agreement between measures [7]. Bland-Altman includes
identification of bias, for example if the mean difference in
EPOC® and CBC measurements lean positive or negative,
as well as the establishment of upper and lower limits of
agreement (±1.96 SD). Hemoglobin interchangeability be-
tween EPOC® and CBC was assessed based on the speci-
fied CLIA criteria (±7%). CLIA cutoff values were coded
as follows to determine the proportion of hemoglobin
values that fell in and outside of CLIA range between zero
and 30min: 0 = difference ≤ 7%; 1 = difference > 7%.
EPOC®-CBC hemoglobin differences ±1 g/dl were coded
as well to determine the proportion of hemoglobin values
within 1 g/dl range or out of range between zero and 30
min: 0 = hemoglobin ≤1 g; 1 = hemoglobin > 1 g. Add-
itional investigation of EPOC® and CBC Interchangeability
was assessed based solely on EPOC® measurements of
hemoglobin levels. The proportion of hemoglobin values
within the ±7% CLIA range, and within the ±1 g/dl clinic-
ally significant range between zero and 30min was calcu-
lated. Furthermore, changes in hemoglobin differences
were explored according to medical population. The pro-
portion of hemoglobin values ±1 g/dl within 30min were
computed according to cardiac surgery, general surgery,
and non-surgery medical populations. Finally, t-tests were
conducted to assess statistical significance with mean
CLIA measurements, and with mean hemoglobin ±1 g/dl
differences when EPOC® measurements are ≤7 and when
> 7. ANOVA testing was performed to evaluate mean
hemoglobin differences across population types. Statistical
Package for the Social Sciences (SPSS) software was uti-
lized to perform all coding and data analysis. Statistical
significance for data analysis was determined using alpha
level 0.05.
Results
When EPOC® and CBC hemoglobin were drawn within
30min of each other, 51% (86 of 170) of lab comparison
points had an absolute difference of < 7 and 49% (84 of
170) had an absolute difference ≥ 7%. In the same group,
73% (124 of 170) of lab comparison points fell within ±1
g/dL of each other, and 27% (46 of 170) had differences
that were > ±1 g/dL (Fig. 1).
Bland-Altman analysis demonstrated that the mean dif-
ference between EPOC® and CBC hemoglobin had a bias of
− 0.268 g/dL that was statistically significant, p = .002, which
indicates that on average, reported EPOC® hemoglobin
values were slightly lower than CBC hemoglobin values at
each comparison point in our sample (Fig. 2). Although this
difference was statistically significant, it was less than our
clinically significant difference of ±1 g/dL.
When the measured EPOC® hemoglobin was < 7 g/dL,
30% of the EPOC® and CBC hemoglobin values were
within ±7% of one another, and 57% were within ±1 g/
dL. When the measured EPOC® hemoglobin was within
≥7 g/dL, 55% of the EPOC® and CBC hemoglobin values
were ± 7% of one another, and 76% were within ±1 g/dL.
Furthermore, t-tests determined that mean differences
between the percent of hemoglobin values within the ±
7% range, and the percent of hemoglobin values within
the ±1 g/dL range as a function of the measured EPOC®
hemoglobin value were statistically significant, 3.01, p <
0.01 and − 3.42, p < 0.01 respectively.
The EPOC® versus CBC relationships also changed as a
function of our patient population breakdown. The differ-
ence between EPOC® and CBC hemoglobin was within ±
1 g/dL for each population as follows: 77% of the time for
cardiac surgery patients, 58% of the time for general sur-
gery patients, and 72% of the time for non-surgical pa-
tients. ANOVA analysis determined mean differences in
hemoglobin levels among populations (0-30min) were
statistically significant, F (2, 167) = 5.051, p = 0.007. Post-
hoc Tukey’s HSD further revealed mean differences
among General Surgery and Cardiac populations. General
Surgery populations were statistically significant from
both Cardiac and Non-surgical / medical populations, p <
0.05 while Cardiac patients were statistically significant
from General Surgery patients, p < 0.02.
Discussion
While there are studies that compare POC versus cen-
tral laboratory parameters in both normal and critically
ill patients, there are none to our knowledge that specif-
ically look at hemoglobin values in patients suffering
Table 1 Average units of each blood product transfused for the patients that had EPOC® and CBC hemoglobin tests drawn within
30 min of each other stratified by patient population
0–30 Minutes Group Cardiac Surgery General/Trauma Surgery Non-surgical Procedure Medical
# of Patients 49 20 6 15
Avg PRBC 17.8 23 16 18.6
Avg FFP 10.8 12.9 8 11.5
Avg Platelets 5.7 5 3.3 4.3
Avg Cryoprecipitate 3.3 2.5 1.5 2.2
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Fig. 1 Hemoglobin Difference vs. Time Plot for time 0–30 min. Points that fall within y = 1 and y = − 1 represent clinically insignificant differences
between the EPOC® and CBC hemoglobin values
Fig. 2 Bland-Altman Analysis (EPOC®-CBC Differences / Measurement Means). Demonstrates a negative bias for EPOC®
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from large volume blood loss requiring massive transfu-
sion [8, 9]. This is a unique, high risk patient population
that can experience substantial morbidity and mortality
in the setting of imprecise transfusion strategies. POC
testing has the potential to revolutionize resuscitation of
these patients. It is generally agreed upon among critical
care providers, that in the setting of massive blood loss
with shock, measured hemoglobin concentrations do not
accurately reflect circulating hemoglobin levels, and pro-
viders should initially transfuse patients to adequately
correct their abnormal vital signs regardless of lab mea-
surements. However, there is a period of time during a
resuscitation when a patient’s vital signs have normal-
ized and there is some uncertainty about whether to
continue or stop transfusions. Typically there is a delay
in getting lab results from central laboratory tests, which
could result in patients receiving more or less blood
products than they should. At our institution, this delay
is on average around 30 min. This key point is where
POC hemoglobin testing has potential to improve treat-
ment strategies. Prior studies comparing core versus
POC laboratory results in critically ill patients have
questioned the reliability of POC hemoglobin measure-
ments. Allardet-Servent et al. compared the POC
Siemens RAPIDPoint® 500 blood gas system to their hos-
pital’s central laboratory analyzer in 314 paired samples
that were collected prospectively from 51 critically ill pa-
tient, and they found that all tested parameters except
for hemoglobin satisfied CLIA criteria of interchange-
ability [8]. The EPOC® device uses conductivity to
measure hematocrit [5]. The hemoglobin concentration
is calculated from the measured hematocrit with the
formula: Hemoglobin (g/L) = Hematocrit (decimal
fraction) × 340 [10–12]. Conductometric measurements
are affected by changes in temperature, electrolyte
concentrations, and protein concentrations within the
sample [10, 13]. While conductivity-based hematocrit is
considered accurate for most physiologically normal pa-
tients, its accuracy is affected by changes in sodium
levels, changes in protein concentrations, administration
of crystalloid and colloid volume expanders, cell saver
transfusions, anticoagulants used in extracorporeal
membrane oxygenation (ECMO) and cardiopulmonary
bypass for cardiac surgery, and the presence of elevated
white blood cell counts, which were common in our
patient population [10, 13]. This method also assumes a
normal mean corpuscular volume (MCV) concentration,
which can lead to inaccuracy since it is possible for
normal healthy subjects to have MCV values that fall
outside the normal range [14, 15]. Maslow et al. evalu-
ated three different POC devices in 24 patients undergo-
ing cardiac surgery. They demonstrated that POC
hemoglobin and hematocrit measurement bias, while
although low and technically acceptable, it varied as a
function of the hemoglobin level and as the clinical context
changed, for example intraoperatively versus postopera-
tively [16]. Chen et al. conducted a head to head compari-
son of the EPOC® device to a central lab analyzer as well as
number of other commercially available POC devices in
patients undergoing cardiopulmonary bypass [10]. The
EPOC® conductometrically measured hemoglobin was
compared to a co-oximetrically measured hemoglobin.
They reported a bias of only 2.78%, which was surprisingly
lower than all other POC devices they evaluated, even with
the hematocrit result range varying widely from 24 to 45%
[10]. These authors did not have an explanation for why
the bias was so much lower for the EPOC® device’s
hemoglobin in their study, especially since it was not con-
sistent with the results of the other POC devices they had
tested which utilized similar technology or prior literature
that demonstrated that other POC devices using conducto-
metric hemoglobin measurements were not that accurate
in similar patient populations [10, 17–19].
We performed a retrospective study comparing point of
care measurements of hemoglobin to central lab testing of
hemoglobin during massive transfusion protocols. Our pur-
pose was to determine the clinical utility, reliability and
interchangeability of POC measurements during MTP. We
were able to demonstrate that in a population of acutely
bleeding patients undergoing massive blood-product trans-
fusion, the EPOC® and central laboratory hemoglobin tests
only fulfill CLIA criteria for interchangeability 51% of the
time. This CLIA criteria is quite rigid and therefore did not
represent clinical utility in our assessment. Our clinical ex-
perts concluded that clinical utility was indeed achieved
with the EPOC device to within ±1 g/dL of hemoglobin.
The EPOC® and core laboratory tests were within our clin-
ically significant range 73% of the time suggesting that the
EPOC® hemoglobin test has clinical utility. For patients
with an EPOC® hemoglobin result of < 7 g/dL, the EPOC®
hemoglobin results were more likely to be significantly dis-
crepant from the core laboratory CBC hemoglobin results,
whereas patients with an EPOC® hemoglobin result ≥7 g/
dL were the most closely correlated with their correspond-
ing CBC results. This discrepancy might be explained by
the rapidity of infused products when hemoglobin levels
are < 7 g/dL as compared to when the hemoglobin levels
are ≥7 g/dL.
There are several limitations to our study. This was a
retrospective review of a heterogeneous population of
bleeding patient requiring massive transfusion. Because
this was a retrospective study, not all of our samples
were collected at the exact same time, and although this
makes it more of a real-world type scenario, it allows for
bias from actual differences in hemoglobin values at dif-
ferent times to affect our results. We arbitrarily chose
60min to be the cutoff for our inclusion criteria to in-
crease our sample size. As a result there was potential
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that differences between EPOC® and CBC hemoglobin
values were actually due to differences between the two
hemoglobin values at different points in time, and not
just from intrinsic variability between the lab tests given
that these patients were actively bleeding, receiving large
volumes of colloid and crystalloid, and various other
medications and interventions that could all potentially
affect hemoglobin values. We attempted to account for
this by limiting our analyzed population to those who
had tests drawn within 30min of one another based on
statistical analysis that demonstrated statistically insig-
nificant differences between these time points. Further-
more, the 4PRBC: 4FFP: 1PLT ratio of blood products in
our MTP is the standard release of products from the
blood bank; however, it is up to the provider which
products are actually given and when. This means there
was no standardized timing of hemoglobin checks,
and this was purely at the discretion of the provider.
This made standardization of timing differences be-
tween central lab testing and POC testing unreliable.
Finally, this study was performed at a single-center
with a small sample size.
The results of this study are warranted for our institu-
tion’s procedures and devices, and should be interpreted
with caution at others institutions. A prospective trial
comparing POC and core laboratory hemoglobin values
sampled at the same time in acutely hemorrhaging
patients undergoing massive blood-product transfusion
is needed in order to accurately assess the utility of POC
hemoglobin testing in this patient population.
Conclusions
Similar to previously published data, our study demon-
strates that there are limitations to the accuracy of
point-of-care hemoglobin testing. Specifically, we dem-
onstrated that in critically-ill bleeding patients requiring
massive transfusion of blood products, the EPOC®
hemoglobin test was only within the interchangeability
range of ±7% with our central laboratory’s measurement
51% of the time. However, the hemoglobin values fell
within our clinically acceptable range of ±1 g/dL 73% of
the time which suggests utility for this point-of-care test
in hyperacute situations during which clinicians may
favor the rapidly available POC hemoglobin results with
a margin of error within ±1 g/dL rather than wait an ex-
cess of 30 min for the central lab test result. Anecdotally,
critical care providers at our institution report that
point-of-care hemoglobin testing has resulted in both
miraculous saves and inappropriate over- and under-
resuscitation of bleeding patients. Our current data,
though limited, support the idea that there is utility for
the EPOC® hemoglobin test, but that it has limitations in
this specific patient population. Therefore, providers
must continue to weigh the risks and benefits of utilizing
point-of-care hemoglobin testing on a case-by-case basis
until larger prospective studies are performed in this
unique patient population. Future studies should be pro-
spective comparing both testing methods of hemoglobin
sampled at the same time.
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